BioRay Biopharmaceutical_Providing professional financial news and data related to BioRay Biopharmaceutical, committed to creating a comprehensive and efficient information access channel for users_NewTimeSpace

NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO

Tags：

BioRay Biopharmaceutical IPO NewTimeSpace Research

2026-01-14

ETF
Positive Outlook for Equity-Based Gold and Silver Mining Companies,Maxwealth CSI Shanghai-Shenzhen-Hong Kong Gold Industry Commodity ETF(517520) Rises Over 2%
ETF
NEV Industry Differentiation Intensifies,Guotai CSI New Energy Vehicles ETF(159806) Falls Nearly 1%
ETF
Hwabao WP CSI Financials Theme ETF(159851) Rises Nearly 3% on the Back of Reviving Market Trading Volume
ETF
Urgency of Domestic Semiconductor Material Substitution Rises,Guotai CSI Semiconductor Material Equipment Theme ETF(159516) Gains Over 3%
ETF
Non-ferrous Metals Industry Faces Multiple Opportunities,Harvest CSI Rare Metals Theme ETF (562800) Falls Nearly 2% at Midday
Finance
PRUDENTIAL(02378.HK): Appoints Sir Douglas Flint as Successor to Chairman, to Officially Take Office in May
Finance
CTF SERVICES(00659.HK): Applies for Registration of RMB5 Billion Panda Bonds for Refinancing and Exchange Rate Risk Hedging
Research
NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
ETF
AI-chip export controls eased, semiconductor rally rolls on—Global X China Semiconductor ETF (03191.HK) gains nearly 3%.
ETF
AI Industry Dynamics Intensify,Harfor CSI Artificial Industry ETF (515980) Surges Nearly 4% in Morning Trading

Scan QR Code

Download App